TNFRSF8 and anaplastic large cell lymphoma: However, since 75% of enrolled patients had a diagnosis of ALCL (which is ubiquitously CD30+), and the study was not powered enough to demonstrate a PFS advantage for individual PTCL subtypes, these results can be considered practice changing only for ALCL [56].